SELLAS Life Sciences Group Inc (NASDAQ: SLS) kicked off on Friday, up 8.52% from the previous trading day, before settling in for the closing price of $1.76. Over the past 52 weeks, SLS has traded in a range of $0.77-$2.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 45.94% over the last five years. While this was happening, its average annual earnings per share was recorded 41.33%. With a float of $103.11 million, this company’s outstanding shares have now reached $105.30 million.
SELLAS Life Sciences Group Inc (SLS) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of SELLAS Life Sciences Group Inc is 2.08%, while institutional ownership is 25.57%. The most recent insider transaction that took place on Jun 12 ’25, was worth 14,800. In this transaction Director of this company bought 10,000 shares at a rate of $1.48, taking the stock ownership to the 20,400 shares. Before that another transaction happened on May 30 ’25, when Company’s Director bought 20,000 for $1.69, making the entire transaction worth $33,800. This insider now owns 30,400 shares in total.
SELLAS Life Sciences Group Inc (SLS) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.1 earnings per share (EPS), higher than consensus estimate (set at -0.13) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.63% during the next five years compared to 45.94% growth over the previous five years of trading.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Trading Performance Indicators
Take a look at SELLAS Life Sciences Group Inc’s (SLS) current performance indicators. Last quarter, stock had a quick ratio of 4.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.33, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.36 in one year’s time.
Technical Analysis of SELLAS Life Sciences Group Inc (SLS)
Analysing the last 5-days average volume posted by the [SELLAS Life Sciences Group Inc, SLS], we can find that recorded value of 2.5 million was lower than the volume posted last year of 2.55 million. As of the previous 9 days, the stock’s Stochastic %D was 85.90%.
During the past 100 days, SELLAS Life Sciences Group Inc’s (SLS) raw stochastic average was set at 72.78%, which indicates a significant decrease from 97.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1113 in the past 14 days, which was lower than the 0.1301 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7835, while its 200-day Moving Average is $1.3922. Now, the first resistance to watch is $1.9677. This is followed by the second major resistance level at $2.0253. The third major resistance level sits at $2.1307. If the price goes on to break the first support level at $1.8047, it is likely to go to the next support level at $1.6993. Now, if the price goes above the second support level, the third support stands at $1.6417.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Key Stats
The company with the Market Capitalisation of 201.12 million has total of 105,297K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -30,880 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -6,600 K.
